October 21, 2025 a 04:38 pm
PFE: Analysts Ratings - Pfizer Inc.
Pfizer Inc., with its extensive range of biopharmaceutical products, continues to receive a mixed set of analyst ratings. Analysts have been observing a shift towards more cautious stances, with an increasing number of 'Hold' ratings. The current sentiment reflects a nuanced perspective, attributing to various factors including product diversification and market conditions.
Historical Stock Grades
The recent analyst ratings for Pfizer as of October 2025 show a significant leaning towards 'Hold', signifying a neutral outlook. There is a notable decrease in 'Strong Buy' ratings compared to earlier months, indicating a more conservative approach among analysts.
| Rating Category | Number of Analysts | Score |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 7 | |
| Hold | 15 | |
| Sell | 1 | |
| Strong Sell | 0 |
Sentiment Development
Throughout the past year, the 'Hold' ratings have seen a steady climb, suggesting increased analyst caution towards Pfizer Inc. The steady number of 'Buy' and reduction in 'Strong Buy' ratings further reinforce this sentiment.
- Monthly increase in 'Hold' ratings suggests hesitance among analysts.
- Mostly consistent 'Buy' ratings with slight fluctuations.
- 'Strong Buy' ratings have declined from 4 in late 2022 to 1 in late 2025.
- Overall rating volume remains similar, reflecting stable interest but cautious outlook.
Percentage Trends
Examining the shifts between different recommendation categories reveals a trend of increased conservatism. This is particularly evident with a rise from a 10% 'Strong Buy' in 2022 to a mere 3% in 2025.
- 'Strong Buy' ratings diminished from 13% to 3% over the year.
- 'Hold' ratings increased by 13% from 2023 to 2025, rising to 65% of total ratings.
- 'Buy' ratings displayed minor variance, suggesting stable but cautious optimism.
- Clear sentiment pivot from aggressive to conservative recommendations among analysts.
Latest Analyst Recommendations
The recent months have seen analysts maintaining their current rating perspectives for Pfizer, with no major shift in sentiment. The recommendations continue to lean towards holding previous positions.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-10-10 | Equal Weight | Equal Weight | Morgan Stanley |
| 2025-10-03 | Neutral | Neutral | B of A Securities |
| 2025-08-06 | Neutral | Neutral | B of A Securities |
| 2025-08-06 | Neutral | Neutral | Citigroup |
| 2025-08-06 | Equal Weight | Equal Weight | Morgan Stanley |
Analyst Recommendations with Change of Opinion
This segment highlights shifts in sentiment, perhaps reflecting changing market dynamics or reevaluated growth projections for Pfizer. Recent downgrades and upgrades reflect a complex perception among analysts.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-04-08 | Neutral | Buy | Goldman Sachs |
| 2024-08-08 | Outperform | Neutral | Daiwa Capital |
| 2024-03-22 | Hold | Buy | Argus Research |
| 2024-01-04 | Market Perform | Outperform | TD Cowen |
| 2023-10-16 | Buy | Hold | Jefferies |
Interpretation
The pattern of increased 'Hold' ratings points to a cautious market sentiment about Pfizer, characterized by stable yet less aggressive projections. The consistency in recommendations and minor shifts in opinion reflect a reserved approach, possibly due to market uncertainties or internal strategic shifts. Limited 'Strong Sell' ratings indicate a lack of severe concern. However, the decline in 'Strong Buy' ratings suggests reduced enthusiasm about significant growth potential.
Conclusion
Overall, Pfizer's analyst ratings suggest a balanced yet cautious market view. While the company's diverse product portfolio ensures a stable market position, analysts exhibit restrained enthusiasm about significant short-term growth. The shift towards more 'Hold' ratings and fewer 'Strong Buys’ indicate tempered expectations. Investors considering Pfizer must weigh the solid market stability against the modest projections for robust growth. This sentiment underscores the need for ongoing assessment of Pfizer's strategic initiatives and broader market conditions.